Researchers in California and Washington are proposing a novel approach to treating advanced cancer that involves sticking cancer cells in place using an antibody that strengthens the bonds between cells—preventing the spread of cancer cells throughout the body.
The monoclonal antibody 19A11, developed by Professor Barry Gumbiner at the University of Washington (UW) and Seattle Children’s Research Institute, binds E-cadherin, a protein that helps cells stick together, especially in epithelial layers that line the skin, the gut and other organs.
Cadherins and other adhesion molecules are important for maintaining the structure of vessels and preventing cancer metastasis, as well as playing a role in inflammation and related conditions such as Crohn’s disease and inflammatory bowel disease.
Adhesion is mediated by the trans binding of Ecad ectodomains (extracellular regions) from opposing cell surfaces. Deficiencies in Ecad adhesion result in the loss of contact inhibition and increased cell mobility and are associated with the metastasis of gastric cancer, breast cancer, colorectal cancer, and lung cancer. Consequently, strategies that activate or strengthen Ecad adhesion may have potential applications in reducing cancer metastasis. Researchers have previously found that treatment with 19A11 can prevent spread of lung cancer cells in mice.
Search Antibodies Search Now Use our Antibody Search Tool to find the right antibody for your research. Filter
by Type, Application, Reactivity, Host, Clonality, Conjugate/Tag, and Isotype.
Bin Xie, graduate student in biophysics, Professor Sanjeevi Sivasankar, Department of Biomedical Engineering, and colleagues at University of California Davis and UW, carried out detailed studies of how 19A11 binds to E-cadherin. Using X-ray crystallography, they found that the antibody binds E-cadherin near the site where it attaches to another E-cadherin molecule. With a combination of simulations and atomic force microscopy, they showed that 19A11 has two binding modes, one of which increases the adhesive strength of E-cadherin. That increased adhesion comes from the formation of a type of chemical link called a salt bridge between the molecules.
“Our results identify mechanistic principles for engineering antibodies to enhance Ecad adhesion,” according to their paper, published recently in Proceedings of the National Academy of Sciences.
By better understanding how this antibody can increase stickiness between cells, the researchers hope to find ways to design even more effective treatments along the same lines.